Apixaban antithrombotics  

Eliquis - BMS-562247 - BMS562247 - BMS 562247      

Select             pdf
Trial Studied trt Control trt patientstagsROB Trial resultMajor bleedingAll cause death

acute coronary syndrome  

APPRAISE-1 (10mg od), 2009      NCTapixabanplaceboLow risk of bias negative
APPRAISE-1 (2.5 mg bid), 2009      NCTapixabanplaceboLow risk of bias negative
APPRAISE 2, 2011      NCTapixabanplaceboLow risk of bias negative 153%8%

atrial fibrillation  

AVERROES, 2011        NCTapixabanaspirinineligible for VKALow risk of bias suggesting 14%-21%
ARISTOTLE, 2011        NCTapixabanwarfarin standard doseLow risk of bias conclusive-30%-11%
phase 2 apixaban    NCTapixabanwarfarin standard doseExploratory -

pulmonary embolism  

AMPLIFY-EXT 2.5mg, 2012      NCTapixaban 2.5mgdiscontinuationLow risk of bias suggesting-51%
AMPLIFY-EXT 5mg, 2012      NCTapixaban 5mgdiscontinuationLow risk of bias suggesting-75%
AMPLIFY, 2013      NCTapixaban (without LMWH)LMWH/VKA DOAC without heparin Low risk of bias suggesting-69%-21%

thrombosis prevention  

ADOPT, 2011      NCTapixabanenoxaparinmedical patientsLow risk of bias suggesting153%
ADVANCE 3, 2010    NCTapixabanenoxaparinhip surgeryLow risk of bias suggesting22%199%
ADVANCE 2, 2010      NCTapixabanenoxaparin (europe regimen)knee surgeryLow risk of bias suggesting-35%∞%
APROPOS 2.5mg, 2007    NCTapixabanenoxaparin (US regimen)knee surgeryLow risk of bias negative∞%
ADVANCE-1, 2008      NCTapixabanenoxaparin (US regimen)knee surgeryLow risk of bias suggesting-50%0%

venous thrombosis  

AMPLIFY-EXT 2.5mg, 2012      NCTapixaban 2.5mgdiscontinuationLow risk of bias suggesting-51%
AMPLIFY-EXT 5mg, 2012      NCTapixaban 5mgdiscontinuationLow risk of bias suggesting-75%
Botticelli DVT, 2008      NCTapixaban (without LMWH)LMWH/VKAExploratory -
AMPLIFY, 2013      NCTapixaban (without LMWH)LMWH/VKA DOAC without heparin Low risk of bias suggesting-69%-21%